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Pharmacogenomics:
A Primer for Policymakers
Leslie Tucker, Consultant
Overview — Researchers are exploring how genetic variations among
individuals may help explain why a drug can work well in some people and
poorly (or not at all) in others, including those who appear to have the same
disease. Pharmacogenomics, as this new field is called, aims to help physicians
make use of genetic tests to distinguish among patients whose genetic characteristics predispose them to respond in certain ways to certain medicines.
If physicians can use this information to quickly and reliably choose the appropriate drug at the most effective dose for each patient, they may produce
better patient outcomes and save health care dollars. An understanding of the
genetic variables that influence drug response could also help pharmaceutical
companies design new, more effective therapies. Although it is early in the
development of pharmacogenomics, there are indications that this promising
new technology has begun to challenge public policies to keep pace. Issues
surrounding the safety, access, cost, and ethical dimensions of new clinical
genetic tests and targeted drug therapies will need to be addressed if pharmacogenomics is to fulfill its potential. Conceptually, few of the issues raised by
pharmacogenomics are unique to the field—or even to genetics—but all will
have to be considered explicitly in the context of this new technology.
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Pharmacogenomics:
A Primer for Policymakers
Americans and their health insurers—both private and public—spend more
than $250 billion per year on pharmaceuticals, and for most of the past 15
years that spending has been the fastest growing component of health care
costs.1 According to some estimates, it can cost nearly $1 billion to bring
one drug to market.2 A large share of that amount underwrites clinical trials that drug manufacturers carry out in order to prove a drug’s safety and
effectiveness. Yet many currently approved drugs are effective in less than
50 percent of the people treated with them,3 and adverse drug reactions are
the sixth leading cause of hospitalization and death in the United States.
Building on the tools and knowledge generated by the Human Genome
Project, pharmacogenomics is a rapidly growing field that explores the
contribution of genetics to drug safety and efficacy—specifically, how genetic variations affect individuals’ responses to drugs. Genes determine the
make-up of human proteins, including enzymes, receptors, transporters, and
other molecules involved in drug and disease pathways (see illustration, next
page). Pharmacogenomics uses genetic tests to classify patients and diseases
according to variants in these genes. This information can help predict who
will or will not benefit from a particular drug, at what dose, and which patients may be at risk for adverse reactions. Eventually, pharmacogenomics
may be used to design new drugs and to identify candidates for preventive
drug regimens long before disease symptoms are apparent.
Although headlines have proclaimed a coming genetic “revolution” in health
care, most of the anticipated advances in pharmacogenomics are still in the
early research stage. Massive, multi-institutional studies are just beginning to
unravel the genetic basis of today’s most important diseases, and to identify
the environmental, behavioral, and dietary factors that interact with gene
variation to affect drug response. So far only a handful of drugs “tailored”
to specific genotypes have been developed and approved.
Bringing pharmacogenomics from the realm of basic exploratory genetics
research to safe, effective applications in the doctor’s office will require
enormous investment, collaboration, and innovation across the biomedical
enterprise. Like all new medical technologies, pharmacogenomics will have
to prove that its tools and discoveries produce real added value in treatment
decisions and outcomes before it is widely embraced. It will also require
new regulatory standards, safeguards, and educational initiatives to guide
its path from bench to bedside. Finally, it will cost will money. This paper
describes the opportunities and challenges embodied in this new technology,
current federal efforts to advance the field, and outstanding policy issues
related to safety, quality, access, cost, and ethical implications.
National Health Policy Forum | www.nhpf.org
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Pharmacogenomics Basics: Genes, Proteins, and Drugs
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Genes are segments of DNA. DNA is composed of different combinations
of four nucleic acids, or “bases,” abbreviated A,T,C and G, arranged in
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do most of the work in living cells. Proteins include enzymes (which build
or break down substances), receptors (which serve as signal receivers for
a cell), transporters (which move molecules across cell membranes
and around the body), and many other important molecules.
Genetic instructions for making proteins are “read” or
translated through a process called transcription.
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The nucleic acid sequence of specific genes can vary from
person to person, even within immediate family. This
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natural variation means that at least some of the proteins
made by each person will be different from others.

Protein

Drugs are designed to interact with substances in the body,
most often proteins. Sometimes, genetic differences can

affect how well a particular drug serves its intended function by influencing how that drug is activated, broken down,
transported, or eliminated by the body, as well as the fit
between the drug and its protein target.
Protein A

Drug cannot interact

Protein A

Protein B

Protein B

Drug binds & interacts

Blood Vessels

Pharmacogenomic technologies try to detect genetic variations in a patient, or among patient
populations, to help doctors select the drug compounds and doses that are most likely to work.
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CURRENT APPLICATIONS
Some genes control pharmacodynamics: how the drug affects the body. Others control pharmacokinetics: how the body absorbs and disposes of a drug
(that is, how the drug is metabolized). Pharmacogenomic techniques work
with both processes. Examples include:


Subtyping common diseases to help physicians choose the right drug
therapy — What appears to be one disease in a clinical setting can turn

out to be several different diseases at the molecular level, each requiring
a different therapy. Cancers, for example, are a particularly promising
area for pharmacogenomics because genetic “glitches” direct tumors
to grow and spread in different ways and their response to treatment
often depends on these unique characteristics.4 The classic example of a
pharmacogenomic drug, Herceptin, is a highly effective therapy in the
15 to 25 percent of breast cancers that have a particular genetic variant
that causes marked overexpression of the HER2 protein (a cell growth
promoter) and is useless against breast tumors without that variant.5
This variety in the genetic underpinning of disease is true for many
other diseases as well. For example, heart attacks are associated with at
least 20 different genetic variations (many of which also have roles in
inflammation or immunity),6 suggesting that there are multiple types
of heart disease that are potentially treatable in different ways.


Subtyping patients to help guide drug dosing regimens (see illustration
below) — Drugs are broken down (metabolized) in the body by enzymes.

One family of enzymes called cytochrome P (CYP) 450 is responsible for

Rx

Rx

Rx

Rx

Rx

Source: Adapted from Felix W. Frueh, U.S. Food and Drug Administration, “Personalized Medicine, What Is It? How Will It Aﬀect Healthcare?”
slides from the 11th Annual FDA Science Forum, April 26, 2005; available at www.fda.gov/Cder/genomics/scienceForum2005.pdf.
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breaking down more than 30 different classes of drugs, including antidepressants, antipsychotics, beta blockers, and some chemotherapeutic
agents. Individual variations in the genes that produce these enzymes
can cause different people to metabolize the same drug differently: less
active or inactive forms of CYP enzymes that are unable to break down
and efficiently eliminate a drug from the body (“slow metabolizers”)
can cause the drug to build up and lead to severe overdose in patients,
whereas very active forms (“ultrarapid metabolizers”) can cause the body
to clear itself of a drug before it has had a chance to work. Identifying
which variant(s) a patient has could help physicians determine the appropriate dose of some medications to achieve therapeutic effects more
quickly and avoid potential drug reactions. For example, every year in
the United States, 2 million surgical and cardiac patients take the blood
thinner warfarin (Coumadin®) to prevent blood clotting, but finding the
correct dose for each person is notoriously difficult and mistakes can be
deadly. Researchers found that differences in a gene called VKORC1,
in tandem with specific CYP enzymes, influence how much warfarin
is optimal for each person, a discovery that led the U.S. Food and Drug
Administration (FDA) for the first time to recommend genetic testing on
the label of a popular drug. A few clinically important variations in other
metabolic enzymes also have been identified. For example, one version of
the enzyme thiopurine methyltransferase (TPMT) prevents patients from
metabolizing the anticancer drug 6-mercaptopurine (6MP), used to treat
one form of childhood leukemia. Patients who have a specific mutation
in the gene that codes for the enzyme may need less than one-tenth of
the regular dose, and they can die if they receive a full dose.


Identifying individuals who could benefit from prophylactic drug
therapy — Many advocates are hopeful that pharmacogenomics will

enable tailored pharmaceutical interventions to prevent disease. For
example, a risk assessment that takes into account a patient’s genetic
susceptibility to coronary artery disease could result in a lower threshold for prescribing anticholesterol medication than is recommended
for the population at large.7 Pharmacogenomics can also support targeted primary chemoprevention, for example, by identifying women
with BRCA1 and BRCA2 gene mutations who may benefit from using
the drug tamoxifen to prevent breast cancer. The value of pharmacogenomics for disease prevention is currently limited by the fact
that gene variants discovered so far explain only a small proportion
of overall risk; however, ongoing discovery and characterization of
disease “susceptibility” genes may improve risk prediction.8
In addition to its clinical applications, pharmacogenomics has some potential to help drug companies and the FDA bring drugs to market more
quickly. When drugs fail clinical trials, it is often because they cannot show
a statistically significant therapeutic effect in a diverse population; other
drugs fail because of safety issues in a small number of trial participants.
Pharmacogenomics could potentially reduce the risk of these expensive failures by enabling companies to identify and recruit clinical trial participants
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who are likely to respond favorably to the drug and to eliminate subsets
of patients whose genotypes make them likely to suffer adverse reactions,
thus reducing the time and number of subjects necessary to prove safety and
efficacy. For drugs that have failed trials or been recalled from the market

CYP Enzymes and Psychotropic Drugs
Psychiatric drugs have long been a priority for
pharmacogenomics research because of the economic and social burden of mental illness and
because it is very difficult for physicians to predict
who will respond best to which of the many available drugs. Selective serotonin reuptake inhibitors
(SSRIs) have become the first-line drugs in the
treatment of depression, but physicians must
choose among more than two-dozen branded
products in this drug class with little definitive
clinical evidence to determine which is most likely
to work for which patient. In addition, finding
the correct dose usually involves a process of trial
and error, which can lengthen the time until treatment begins to help a patient. One-third of people
treated with antidepressants do not respond to any
medication or suffer such intolerable side effects
that they cannot continue with the drugs.*
Researchers know that SSRIs are metabolized by
the CYP 450 family of enzymes, and genetic tests
recently have become commercially available that
can identify whether an individual has the “slow,”
“rapid,” or “ultrarapid” metabolizer version of the
genes that code for these enzymes. Researchers
are now trying to uncover the specific associations
between genetic variants in the CYP system and
the effectiveness and side effects of specific SSRIs
along with other antidepressants. To succeed,

researchers will have to isolate the effects of CYP
450 differences from the effects of other known
and suspected genetic variants that could influence
response to SSRIs, as well as differences in diet,
exercise, the presence of other health conditions,
other drugs the patient may be taking, and so on.
The task is so complicated that government agencies in both the United States and Europe have
established research networks to divide the work
and share data.†
Even if the specific effects of CYP 450 status become
known, it is unclear how much or how soon such
information will be available to assist physician decisions about selecting specific SSRIs and their doses
for individual patients. Physicians will look for
evidence that prescribing based on CYP status improves patient outcomes—evidence that, according
to a recent AHRQ report, does not yet exist.‡ Many
will also look to professional practice guidelines to
inform genetic testing criteria and to help translate
genetic test lab results into useful prescribing information; however such guidelines will require
even more detailed levels of evidence that will take
more time and resources to develop.§ Ultimately, a
physician may decide that the combined influence
of other variables in depressed or anxious patients
may outweigh the predictive value (and expense)
of a genetic test to look only at CYP status.

* Arline Kaplan, “Advances in Pharmacogenomics Reduce Side Effects and Save Lives,” Psychiatric Times, XXII, no. 7 (June 1, 2005); and J. Kirchheiner et al., “Pharmacogenetics of antidepressants and the antipsychotics: the contribution of allelic variations to the phenotype of drug response,”
Molecular Psychiatry, 9, no. 5 (May 2004): pp. 442–473.
† These include centers within the Pharmacogenetics Research Network (PGRN), supported by the U.S. National Institutes of Health (NIH) and the
Genes and Depression study (GENDEP), supported by the European Union and involving scientists and clinicians from ten countries.
‡ D. B. Matchar et al., Testing for Cytochrome P450 Polymorphisms in Adults With Non-Psychotic Depression Treated With Selective Serotonin
Reuptake Inhibitors (SSRIs), Evidence Report/Technology Assessment No. 146, AHRQ Publication No. 07-E002, Agency for Healthcare Research
and Quality, November 2006; available at www.ahrq.gov/downloads/pub/evidence/pdf/cyp450/cyp450.pdf.
§ Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, “Recommendations from the EGAPP Working Group:
testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors,” Genetics
in Medicine, 9, no. 12 (December 2007): pp. 819–825.
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for safety reasons, pharmacogenomics could potentially lead to relabeling
and approval of these products for populations whose genotypes indicate
they would benefit from, or not be harmed by, the drug. Finally, a better
understanding of how genetic variations affect specific disease processes
and drug responses may help identify new targets for drug development.
Many see this as the ultimate promise of pharmacogenomics.

CHALLENGES
Pharmacogenomics carries great promise; however, the degree to which
that promise is realized will depend on effective implementation of myriad
steps and policy decisions that must be made by a variety of organizations
in both the public and private sectors.

Basic Research
The most obvious hurdle for pharmacogenomics is the complexity of the
underlying science. The sequencing of the human genome, completed in
2001, and the HapMap (see text box), completed in 2007, has given scientists
a “parts list” and a companion catalogue of variations for the workings of the
genome. However, the key to fully exploiting the potential of pharmacogenomics is understanding how
the relationships among
Deciphering
There are roughly 22,000 genes amidst the 3 billion
genes, disease processes,
Genetic
Variation
DNA “bases” (designated by the letters A, T, C and
drugs, and environmenG) that make up the human genome (see illustratal factors work at the
tion, page 4). While more than 99 percent of those
molecular level, and that
DNA bases are identical from person to person, there are still an estimated
understanding is still very
10 million single-letter variations—called single nucleotide polymorphisms
rudimentary. Some genes
(SNPs, pronounced “snips”)—in the human genetic sequence. Most of these
(or their products) and
variations are believed to be biologically insignificant, but a small fraction of
the drugs that affect them
them are known to alter the function of a gene—often only slightly, but someare relatively well undertimes significantly. The effect of many slightly altered genes interacting with
stood, but they are the
each other, combined with environmental factors, may lead to increased risk
exception, not the norm.
for a particular disease or shift a biochemical pathway normally targeted by
Indeed, many believe
a drug. Scientists have mapped (the “HapMap”) where SNPs tend to occur in
that the handful of gethe genome.* However, the arduous process of deciphering which variations
netically targeted drugs
(and combinations) account for what biological effects, including drug effects,
already on the market
is immensely complex and has only just begun.†
are the “low-hanging
fruit”; most involve single genes (“mongenic”)
* David A. Hinds et al., “Whole-Genome Patterns of Common DNA Variation in Three Human Populations,”
Science, 307, no. 5712 (February 18, 2005): pp. 1072–1079; and International HapMap Consortium, “A
whose influence was dissecond generation human haplotype map of over 3.1 million SNPs,” Nature, 449 (October 18, 2007): pp.
covered (sometimes by
851–861.
accident) after the drug
† Genome-wide association studies (GWAS) represent a powerful approach to detecting associations between
was already in use. In
genetic variants and common diseases, however, such studies are not designed to discover the specific mechanisms involved. If an association is confirmed, its effect generally must be elucidated using different techniques.
contrast, most important
For information on NIH-supported GWAS, see www.genome.gov/20019523.
biological processes are
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governed by several genes (“polygenic”) and are often the result of variations in those genes interacting with each other and with something in the
environment. How a person responds to a particular drug, for example,
can be influenced by variables such as diet, other medications, and other
underlying conditions, in addition to his or her particular set of genes.
The cost and technical challenges of putting together the infrastructure
needed to support research on the scale required to discover and characterize genetic influences within complex interactions are enormous. Given
so many variables, association studies and clinical trials need to enroll
large numbers of participants and be supported by robust information
management systems that can adapt to upgrades in the methods of genomic analysis.9 Moreover, while investment in genomic technologies has
driven costs down significantly over the last decade,10 it is still expensive
to sequence and analyze the amount of genetic material needed to pinpoint gene-drug-disease interactions. Once a specific genetic influence is
determined, additional work is needed to explain the molecular pathways
and mechanisms of action. Few individual institutions have the resources
to mount such studies, so collaborations are a must.11

Co-Development of Pharmaceuticals and Genetic Tests
One major challenge for both industry and regulators will be integrating
genetic testing into drug development, approval, and marketing. The development of a genetically targeted drug will require the development of
an associated genetic test, first to locate the gene target for drug development and then to identify patients who possess the targeted gene variant
and therefore are candidates for the new therapy. As a practical matter, few
pharmaceutical companies have expertise in the diagnostics business. The
two industries have evolved separately, with distinct cultures, regulatory
mechanisms, product lifecycles, and commercialization pathways. Therefore, drug companies that wish to pursue pharmacogenomics as part of
their drug development strategies will have to either learn diagnostics or
partner with companies that already know the field. In addition, regulators and third-party payers will need to develop policies to ensure that
clinically validated genetic tests needed to inform prescribing of approved
pharmacogenomic drugs are appropriately promoted with the drug and
are accessible to physicians and their patients.

Translating Research into Treatment
Research to discover associations between genes, disease, and drugs will
be of little practical value without an understanding of how those findings should translate into actual treatment decisions. For example, as
noted above, doctors now know that an individual’s response to warfarin
therapy is partially but significantly influenced by two genes, and a test
is available to detect whether a patient has slow or fast metabolizer variants of these genes. However, knowing which genetic variants a patient
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has does not tell the physician how to adjust the warfarin dose. Should
doses be smaller? Should there be more time between them? Or should
a different anticoagulant therapy be used? Further complicating matters,
these genes explain less than half of the observed variability in patients’
responses to standard warfarin dosing.12 What other factors—genetic or
otherwise—should be considered in making a dosing decision? In fact,
gene-based dosing guidelines have not been developed for warfarin13 or
any other CYP-metabolized drug because there is, as yet, no clear understanding of the optimal doses for slow or rapid metabolizers. Moreover,
the rate at which the body clears a drug, and thus the likely corresponding
adjustment to dose, varies by drug. This variability also applies to predicting side effects and drug interactions. Finally, the effects of the same genetic
variant may be quite different in different populations, again reflecting the
interplay of many variables. Thus, each drug must be studied individually
across multiple groups,14 which is a massive undertaking.

Until recently, most
large pharmaceutical
companies have been
ambivalent about
making significant investments in pharmacogenomics.

Health Information Technology
Basic, translational, and clinical research and applications in pharmacogenomics will require the sharing, storage, and management of massive
amounts of information across multiple organizations and institutions,
from the U.S. National Institutes of Health (NIH) and industry gene databases to point-of-care decision support tools.15 Information technology
systems will need operating rules and a common nomenclature that can
accommodate the types and level of detail of pharmacogenomic-related
data collected in different settings (the research center, the lab, the clinic,
the surveillance registry, etc). Computational and analytic methods also
will need to embrace bioinformatics (from the genomic testing) and clinical
informatics (clinical trials and health care data).

Pharma Buy-In
Until recently, most large pharmaceutical companies, which control the
lion’s share of capital for pharmaceutical research and development, have
been ambivalent about making significant investments in pharmacogenomics. Some pharmaceutical executives worry that by segmenting diseases
and patient populations, pharmacogenomics could shrink the market for
“blockbuster drugs” that are the bedrock of the industry.16 In addition,
because the traditional pharmaceutical business model generally depends
on mass advertising and billion dollar sales, many experts believe these
companies simply could not be successful developing drugs that serve
only a small portion of the population.
However, the number of profitable drugs coming off patent, shrinking drug
pipelines, and persistent (and expensive) consumer and regulatory concerns
over drug safety are forcing many pharmaceutical makers to reassess their
current research methods and business portfolios. Most pharmaceutical
companies now routinely collect pharmacogenomic data from their clinical
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trial participants for exploratory in-house analysis, and many have begun
to invest in building capacity for pharmacogenomics to support at least a
portion of their future drug development work. However, a sustained industry commitment to pharmacogenomics research and development will
hinge on many variables, including the economics of “mini-buster” drugs
and well-aligned regulatory pathways for each stage.

Cost
New pharmacogenomic therapies are likely to be expensive. Many of the
drugs will be biologics (drugs made from human or animal proteins),
the fastest-growing and most expensive group of drugs on the market.
Moreover, both biologics and traditional “small molecule” drugs that are
developed or approved for a genetically defined subpopulation or subcategory of disease are likely to occupy the high end of the pricing spectrum.
A treatment course of Herceptin, for example, can cost upward of $60,000.
Manufacturers argue that premium prices are justified in exchange for the
lower risk and higher certainty that these drugs will work in their target
populations, and that less wasted drug use—that is, less use of drugs on
patients for whom the drug has no effect or serious side effects—would
help offset higher prices. Manufacturers also point out that a drug created
for a limited market still needs to generate enough revenue to offset its
development costs.
Genetic tests also are expensive (between $200 and $3,500) and could become more so even though the cost of the technology is expected to decline.
Genetic test manufacturers are beginning to challenge the practice of “cross
walking” new tests to old tests in order to establish fees, arguing that new
diagnostics should be reimbursed based on the value of the information
provided by the test. There are no standards or mechanisms to determine
the “value” of new tests (though some have been proposed).17 However,
the maker of a new prognostic test for early-stage breast cancer reasons
that the $3,500 price tag is just one-quarter of the cost of chemotherapy for
that condition, and that it will detect and avoid unnecessary chemo for the
estimated 85 percent of patients whose breast cancer will not recur after
surgery.18 Tests such as microarrays or “gene chips” that detect variations
in multiple genes or gene products at one time are also potential cost drivers. Although the tests themselves may not be very expensive, like all tests,
they will produce some false positives that will then take additional testing
and resources to rule out. And the opportunity for false positive findings
is amplified when many genes are tested simultaneously. One group of
researchers dubbed this phenomenon the problem of the “incidentalome.”19
There is also the possibility that these tests could find true positives or
turn up other information—for example, a genetic predisposition to a
particular form of heart disease—that were not part of the original reason
for seeking the test but could lead to expensive medical interventions or
prophylactic drug regimens. These costs may be warranted, but they are
added costs nonetheless.

National Health Policy Forum | www.nhpf.org
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Demonstrating Value
Pharmacogenomic technology will only move forward if developers are
confident that the market is robust enough to justify the investment. The
market for pharmacogenomic (and most other) therapies is mediated by
third-party payers who will want proof that these therapies add value to
health care by holding or reducing costs and improving outcomes—proof
that is currently missing and that will take time and resources to develop.
A widely cited literature review turned up just 11 cost-benefit analyses of
pharmacogenomic interventions, covering a limited range of conditions
with mixed results.20 Today a few of the largest health care organizations,
such as Kaiser Permanente, Aetna, and Partners Health Care, are studying
whether and how they should incorporate pharmacogenomics into their
clinical processes. They are examining parameters like the cost of a pharmacogenomic test, mortality due to adverse drug reactions, prevalence of
the particular genotype being targeted by the test, and whether test results
would change providers’ clinical decisions in ways that improve patient
outcomes—all key to establishing the value of a pharmacogenomic approach
to prescribing a particular drug. These early assessments, in turn, will help
determine how much incentive developers have to invest in this arena and
where their energies would be best directed.

Third-party payers will
want proof that these
therapies add value to
health care by holding
or reducing costs and
improving outcomes.

FEDERAL INITIATIVES
Federal health agencies have undertaken a number of initiatives to facilitate the progress of pharmacogenomics. These include significant funding
and organizational support for public-private sector research networks
designed to broadly share data and research tools, a consultative approach
to evolving new regulations, and efforts to create evaluation methods for
the clinical applications of this developing technology.
The NIH, the nation’s primary driver of basic biomedical and genetics research, has launched several major projects specifically to help genetics
researchers find meaningful associations between genetic variations and
drug response among the 10 million common variations in the human genome. The Pharmacogenetics Research Network (PGRN) is a nationwide
collaboration of scientists created specifically to study the effects of genes
on individuals’ responses to medications, including drugs for asthma, depression, cancer, and heart disease.21 The Genetic Association Information
Network (GAIN) is a public-private partnership that provides industry
and academic researchers access to tissue samples from NIH clinical trial
participants for genetic association studies. A primary objective of the NIH
is to place as much genomic data and research technology as possible in the
public domain, making it accessible to the global research community.
The FDA sees pharmacogenomics as both a tool to help achieve its mission of
ensuring that drugs are safe and effective and as an opportunity to advance
its Critical Path Initiative, which aims to help drug (and other medical product) development keep pace with advances in biomedical research.22 The
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agency has been spearheading discussions with industry about all aspects
of pharmacogenomics and the research and regulatory approaches that
can best promote it.23 FDA and the Arizona-based C-Path Institute,24 a new
private foundation with which FDA collaborates, are coordinating research
consortia that include some of the nation’s largest drug manufacturers as
well as academic researchers to develop new targets (biomarkers) and
research tools for pharmacogenomics and to share preclinical and clinical
research methods and data that may be relevant to assessing drug safety.
The FDA has also developed a Voluntary Genomic Data Submission process
to encourage companies to share data on exploratory genetic biomarkers
they are collecting from clinical trial participants without fear that these
data will be used to delay approval or make it conditional.25 New rules for
“adaptive” clinical trials permit genetic “enrichment” of the study population as a trial proceeds in order to reduce the time needed to demonstrate
a new drug’s safety and effectiveness.26 For companies that want to market
a drug specifically to a genetic subset of patients, the FDA is refining a process and standards for coordinated review and approval of the drugs and
their associated genetic tests, which currently are regulated differently by
separate Centers within the agency.27 Finally, the FDA is negotiating what
pharmacogenomic information must be included on specific drug labels
where evidence of gene-drug interactions is conclusive.
The Centers for Disease Control and Prevention (CDC) and the Agency for
Health Care Research and Quality (AHRQ) support a number of programs
that potentially could answer questions about the value of pharmacogenomics that clinicians, health plan administrators, policymakers, and
patients will be asking as more applications become available. The CDC
created the Evaluating Genomic Applications in Practice and Prevention
(EGAPP)28 initiative to develop an evidence-based method for judging the
usefulness of specific genetic and pharmacogenomic tests as they transition from research into clinical practice. So far, EGAPP has completed four
of six planned evidence reviews, three of which remarked on the lack of
high-quality clinical studies to determine whether the tests affect patient
management decisions in ways that improve outcomes (some tests were
still investigational at the time of EGAPP’s review, so such studies may be
forthcoming). AHRQ spearheads a network of Evidence-Based Practice
Centers that conduct assessments of health care services and technologies,
including the specific pharmacogenomic applications of interest to EGAPP.
In addition, AHRQ conducts research “to advance the optimal use of drugs,
medical devices and biological products” through its Centers for Education
and Research in Therapeutics (CERTs),29 which the agency operates with the
FDA. CERTs could incorporate pharmacogenomic tests into their analyses
of factors that influence the effectiveness of specific drug therapies. Finally,
AHRQ’s Developing Evidence to Inform Decisions about Effectiveness
(DEcIDE) program taps electronic health information databases to conduct
rapid turn-around studies on health services outcomes and comparative
effectiveness; such studies could be instrumental in identifying priorities
for pharmacogenomics clinical research.
National Health Policy Forum | www.nhpf.org
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POLICY ISSUES
How quickly pharmacogenomics develops into a useful clinical toolkit
will depend greatly on how policymakers respond to policy issues
associated with both genetic testing and targeted drug development,
including concerns about safety, access, cost, and potential ethical and
social implications.

Safety and Quality
Pharmacogenomics depends on the availability and reliability of genetic
tests to accurately detect selected genetic markers that are important to drug
therapy decisions as well as the ability of providers to interpret test results
in order to make safe and appropriate use of targeted therapeutics. There is
considerable debate over whether current resources and regulatory requirements are adequate to ensure the safety and quality of genetic testing.30

Pharmacogenomics
depends on the availability and reliability
of genetic tests to accurately detect selected
genetic markers that
are important to drug
therapy decisions.

Genetic tests — Regulatory oversight of genetic testing is spread across the

FDA, the Centers for Medicare & Medicaid Services (CMS), and the CDC.
FDA regulates “test kits” (that is, stand-alone tests that are produced, packaged, and sold with all ingredients and instructions necessary to conduct
the test) as in vitro diagnostic devices (IVDs) that must be approved for
safety and effectiveness before they can be marketed. Today, however, most
genetic tests are not sold as test kits. They are created more or less from
scratch by the clinical laboratories that offer them and have been considered to be medical services provided by the lab rather than commercial
products. Historically, these so-called “home brew” tests have not been
reviewed by FDA. As a result, of the more than 1,200 genetic tests clinically
available,31 fewer than a dozen have been developed as IVDs and approved
by the FDA, leaving the majority of genetic tests without any independent
external review of their analytic or clinical validity before they are offered
to the public.32 As genetic testing technologies grow more complex, many
argue that FDA oversight should extend to laboratory-developed genetic
tests in order to validate the proprietary testing methods, ensure test accuracy and appropriate labeling, provide a means of postmarket monitoring,
and level the regulatory burden for manufacturers who do go through the
effort of developing FDA-approved test kits.33 Indeed, FDA has recently
issued draft regulatory guidance for one new type of laboratory-developed
genetic test called a Multivariate Index Assay (MIA),34 which uses complex
proprietary formulas to calculate the odds of a particular health outcome
based on an individual’s genetic profile. The FDA is assessing whether it
has the resources to actively oversee other categories of lab-developed
tests; however, opponents argue that FDA review of home-brew type tests
would be an intrusion into the practice of laboratory medicine and would
add costs and delays to bringing new tests to market.35
Genetic testing laboratories — CMS and the CDC share responsibility for

ensuring the quality of testing laboratories under the Clinical Laboratory
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Improvement Amendments of 1988 (CLIA).
CLIA specifies standards for laboratory quality
assurance and mandates specialty certification and proficiency testing for laboratories
that perform certain highly complex tests.
Proficiency testing measures a laboratory’s
actual performance on test procedures and
is a key element in determining laboratory
competence. Under CLIA, genetic tests are
considered highly complex, but CLIA regulations—written when genetic testing was still
in its infancy—have not been updated to
mandate proficiency testing standards for genetic testing.36 Currently, most labs performing
genetic testing participate in some level of proficiency testing through programs offered by
private organizations, but such participation
is voluntary and not universal. To address the
gaps, the CDC’s Clinical Laboratory Improvement Advisory Committee announced plans
in 2000 to create a genetic testing specialty
under CLIA,37 and a proposed rule was placed
on the regulatory agenda of the U.S. Department of Health and Human Services (HHS)
for late 2006.38 Before the rule was issued,
however, CMS reversed course, stating that it
believes genetic testing is adequately covered
by existing CLIA standards. Several influential
genetics policy and patient advocacy organizations objected to CMS’s reasoning and filed a
“citizen’s petition,” insisting that the agency
create standards for and mandate participation
in proficiency testing programs for genetics.39
A draft report by the Secretary’s Committee on
Genetics, Health and Society (SACGHS) likewise recommended that the HHS take specific
steps to increase the use of proficiency testing
for genetic tests.40
Provider capacity — To use pharmacogenom-

ics appropriately in patient care, clinicians
must understand exactly what information
a given test can and cannot provide, how to
interpret positive and negative test results, and
what medical management options are available. Studies show that many health care providers are not prepared to make appropriate
use of genetic tests. In one survey, 72 percent
National Health Policy Forum | www.nhpf.org

Some genetic tests are now
being sold over the Internet, prompting widespread
debate about the appropriateness of marketing genetic tests directly to consumers. Though some believe that direct-to-consumer
(DTC) marketing of scientifically validated genetic tests
can empower consumers and encourage patients to
engage their physicians in a dialogue about their health
care, others argue that without the help of a qualified
health care provider to interpret test results, DTC genetic tests can be difficult to understand at best and
useless or harmful at worst.* In addition, a recent U.S.
Government Accountability Office (GAO) investigation
found evidence that some companies are capitalizing
on consumer interest in genetics by selling less-thantrustworthy tests. The genetic tests in GAO’s study
were designed to get consumers to buy expensive food
supplements “personalized” to their DNA,† but there
is nothing to stop a company from offering genetic tests
for more “serious” health-related conditions directly to
consumers,‡ whether or not the test has been reviewed
by the FDA or is performed in a CLIA-certified laboratory. For that reason, the Federal Trade Commission
and the FDA together issued a consumer alert about
DTC genetic tests, while the GAO echoed calls for more
thorough regulatory oversight of genetic tests to ensure
that consumers “have reliable information in order to
determine which tests are accurate and useful.”

Direct-to-Consumer
Genetic Tests

* American College of Medicine Genetics Board of Directors, “ACMG Policy
Statement on Direct-to-Consumer Genetic Testing,” Genetics in Medicine,
6, no. 1 (January/February 2004): p. 60; available at: www.acmg.net/resources/
policies/Direct_Consumer_Testing.pdf.
† Gregory Kutz, U.S. Government Accountability Office (GAO), “Nutrigenetic
Testing: Tests Purchased from Four Web Sites Mislead Consumers,” GAO06-977T, testimony before the Special Committee on Aging, U.S. Senate, July
27, 2006; available at http://www.gao.gov/new.items/d06977t.pdf. The GAO
investigation found that companies purporting to analyze an individual’s
genetic information for personalized nutritional and lifestyle recommendations generally provide the same advice—such as adopting a healthy diet and
avoiding smoking—available from many other sources, but that some go on to
recommend the same “tailored” dietary supplement, costing as much $2,000
per year, to all customers which contains vitamins obtainable at a drug store
for around $35.
‡ Stephen Barrett and Harriet Hall, “Dubious Genetic Testing,” Quack Watch,
April 9, 2002; available at www.quackwatch.org/01QuackeryRelatedTopics/
Tests/genomics.html.
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of nongeneticist physicians rated their own knowledge of genetics as fair
to poor.41 In another study, physicians misinterpreted genetic test results
in nearly one-third of colon cancer cases.42 Such statistics have prompted
calls to revamp provider educational curricula at all levels to emphasize
genetic medicine. However, many doubt that individual providers, particularly busy primary care physicians, will have the interest or the capacity
to become well-schooled in genetics. Rather, they suggest, this is where
professionally developed clinical guidelines—developed by appropriate
specialists or specialty societies and independently reviewed—could prove
valuable to practicing clinicians. Several groups have called on the federal
government to create a mechanism for prioritizing and funding clinical
genetic guideline development. Genetic testing laboratories may also
have a role in ensuring that physicians are able to request and interpret
pharmacogenomic tests appropriately. The National Academy of Clinical
Biochemistry has drafted guidelines recommending that laboratories that
conduct pharmacogenetic testing either have a consultation component
available to provide physicians with a complete interpretation of test results, or work with an organization that can provide such services.43
A complementary approach to ensuring provider competence with pharmacogenomics calls for strengthening the dedicated genetics work force.
Medical geneticists and genetic counselors in particular can serve as bridging professions for nongeneticist physicians, laboratories, and pharmacists.
However, there are only about 3,100 professionals in the United States
who are specifically trained and certified to provide genetic counseling
and clinical genetic services (and the counselors themselves would need
special training in pharmacogenomics), prompting calls to grow the field
with reimbursement or other practice incentives.44
Drug trials, “off-label” prescribing, and postmarket surveillance — The

very precision that characterizes pharmacogenomics could raise new
concerns about drug safety. Pharmacogenomics makes it possible to “enrich” clinical trials with individuals whose genotype suggests that they
will respond well to the drug under study, thereby more quickly demonstrating a drug’s efficacy and reducing the potential for adverse reactions
during the trial. However, enriched clinical trials weighted with “good
responders” may not reveal potentially harmful or toxic effects of the
drug in other populations. FDA requires drugs that have been tested in
defined populations or for specific conditions to be labeled for use only in
those circumstances, but it is well-known that doctors very often prescribe
drugs off label—that is, in doses or situations for which the drug has not
been formally approved.
Physicians prescribe drugs off label for a number of reasons. New off-label
treatments can be grounded in top-notch research that is comparable to the
rigorous studies that the FDA would demand, but they can also be suggested by poorly designed studies, anecdotally by a physician colleague,
or even by a pharmaceutical company representative.45 Sometimes, a
physician’s impetus for off-label prescribing is simply professional hunch
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that may lead to important new indications for a drug; at other times, it is in
response to patient demand for a highly touted therapy, particularly when
there are few acceptable alternatives. Herceptin, one of the first pharmacogenomic drugs, is effective (and labeled) only for patients whose breast
cancer tumors overexpress the HER2 gene, but doctors have prescribed
it for patients without that mutation. In this case, the patient is unlikely
to receive any benefit from this very expensive drug. 46 More worrisome
is the potential that drugs developed to treat or avoid toxicities and/or
adverse reactions in people with a specific genotype could be problematic
and possibly even dangerous when prescribed off label to someone with
a different genotype.
Given these concerns, some have suggested the need for a firmer approach
to managing off-label prescribing, including restrictions on the clinical
use of targeted therapies and tests, enhanced state requirements for physician compliance with product labeling, or the required involvement of
licensed pharmacogenomics counselors in certain types of prescribing
decisions.47 The FDA was given expanded authority under the Food and
Drug Administration Amendments Act of 2007 to impose Risk Evaluation
and Mitigation Strategies (REMS) that could include such provisions if
the agency can show that they are necessary to ensure that the benefits of
a product outweigh the risks. However, mustering the level of evidence
needed to support such a determination is fraught with challenges. In addition, monitoring compliance by health care providers and patients with
any REMS safe-use provisions that FDA might require falls to the drug
manufacturer, who may or may not be well-equipped for the role.

Drugs developed to
treat or avoid toxicities
and/or adverse reactions in people with a
specific genotype could
be problematic and
possibly even dangerous when prescribed
off label.

Such safety concerns may also amplify the need for a comprehensive
system of postmarket surveillance. The current Adverse Event Reporting
System (AERS), through which clinicians and companies are supposed
to report serious and unexpected events that occur once a drug is marketed, receives no more than 10 to 25 percent of actual adverse events,48
making it difficult to identify patterns in a timely manner. A recent report
by the Institute of Medicine on drug safety and public health49 recommends that the FDA strengthen its postmarket surveillance activities by
making better use of existing data sources, such as Medicare claims and
large health maintenance organizations (HMOs) that have computerized
systems for tracking such events. The FDA Amendments Act implements
this recommendation and also gives the FDA more authority to require
new studies or clinical trials of drugs flagged by the surveillance system.
Greater use of electronic health records (EHRs), which would provide
important clinical context for adverse drug events, along with the collection and genetic testing of DNA samples as part of adverse event reporting (with the samples to be deposited in a national registry accessible for
pharmacogenomic association studies) are other possible approaches to
bolster postmarket drug safety. The success of any approach, however,
will depend on whether the FDA is provided sufficient resources to support active surveillance and timely response.50
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Making current drugs safer — Most of the attention on pharmacogenomics

has focused on its role in bringing future drugs to market, but the technology
could also be used to identify genetic risk factors for adverse drug reactions
associated with drugs that have long been staples in American medicine
cabinets.51 One study found that all but 3 of the 27 most commonly identified drugs in adverse drug reaction studies were among the top 200 selling
drugs in the United States at the time.52 Reducing adverse reactions in just
these drugs could have a large impact. However, manufacturers struggling
to fill their pipelines have little incentive to invest in costly pharmacogenomic
research to identify potential genetic contraindications for popular drugs
already on the market. The FDA Amendments Act provides a mechanism
for the agency to compel postapproval studies by the drug sponsor under
specific circumstances53 but only if the agency becomes aware of a new
safety problem with the drug. As a result, much of the research needed to
illuminate pharmacogenomic properties of familiar, widely prescribed drugs
may fall to federal agencies and academic institutions.

Access
Third-party coverage and payment decisions can speed adoption and
use of new technologies or can create serious barriers to access. Health
insurers, including Medicare, will need to consider coverage and reimbursement policies for genetic tests that are performed to guide prescribing decisions and for the drugs that are prescribed on the basis of those
tests. Access to pharmacogenomic technology will also be influenced
by incentives for companies to develop tests and therapies for smaller
populations and for providers to integrate the technology into their
clinical practices.
Coverage of pharmacogenomic tests — Insurers, including Medicare,

make coverage decisions for new diagnostic tests on a case-by-case basis.
Private health plans generally will cover pharmacogenomic tests when they
are required or strongly recommended on an FDA-approved drug label,
such as the HER2 test for Herceptin.54 Coverage of pharmacogenomic
tests that are not required by a label varies, depending mostly on the
plan’s assessment of whether the test is “medically necessary.”55 Medical
necessity criteria usually include high-quality scientific evidence, preferably from clinical trials, that a given test or service is safe and effective
in improving the diagnosis or management of disease at least as much
as established alternatives.56 However, most pharmacogenomic tests are
still too new to have been subjected to the kind of rigorous comparative
effectiveness analysis that would meet the medical necessity threshold.
Until they do, many pharmacogenomic tests are likely to be regarded as
experimental and therefore not covered by private health plans. Notably,
CMS and its local contractors have flexibility to extend conditional coverage to such tests under Medicare’s “Coverage with Evidence” policy (see
text box, next page).
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Medicare has adopted a coverage policy for promising new technologies called
Coverage with Evidence Development (CED), under which CMS may opt to cover
specific medical innovations—such as pharmacogenomic drugs and diagnostics—
that are too “young” to have accumulated the amount of clinical evidence required
to meet the usual standard for coverage, which typically includes published results
from several high-quality controlled clinical trials. CED can actually help develop
that evidence base by linking Medicare coverage to a requirement that patients participate in a registry
or clinical trial, which in turn could support a future decision about unconditional coverage.* A second
element of CED, called “coverage with appropriateness determination,” allows CMS to approve coverage
and reimbursement for an “experimental” new drug or service based on whether a patient has “appropriate” indications (potentially including genetic test results indicating that the patient would respond well
to a particular therapy), similar to private insurers’ use of prior authorizations.† Both of these options give
CMS the flexibility to cover some pharmacogenomic therapies, potentially even before other payers, and
in the process generate data on the clinical usefulness and cost-effectiveness of specific pharmacogenomic
applications that could be mined by other researchers.

Medicare and
Coverage with
Evidence

* Some policymakers and patient groups have challenged the ethics of linking insurance coverage to a requirement for participation in registries, saying
such a requirement could be considered coercive.
† Sean R. Tunis and Steven D. Pearson, “Coverage Options for Promising Technologies: Medicare’s ‘Coverage With Evidence Development,’” Health
Affairs, 25, no. 5 (September/October 2006): pp. 1218–1230.

In contrast to its flexibility to cover new diagnostic tests, Medicare’s
medical necessity clause does not permit coverage of tests—genetic or
otherwise—for preventive screening purposes (unless coverage of a
specific test is mandated by Congress). Thus, genetic testing to identify a
predisposition to a disease for which the patient has no signs, symptoms,
or family history, would not be covered by Medicare.57 Private insurers
generally cover screening tests, including some genetic tests that have
been shown cost-effective in reducing disease burden on their population
mix; however, pharmacogenomic tests are not yet able to prove value on
a population basis.58
Coverage of pharmacogenomic drugs — Current drug coverage and cost

control mechanisms may not work well for pharmacogenomics. For example, formulary placement is key to any health plan’s ability to negotiate
drug prices, guide drug use, and control spending. Formularies are built on
the concept of “therapeutic equivalence” within drug classes, thus allowing
the selection of a preferred drug and exclusion or penalties for substitution.
Drug makers typically prefer formularies that are broken down into more
classes or categories to increase the number of listed products, but payers
prefer formularies that feature fewer drug classes and disease categories
because they provide more negotiating leverage with manufacturers and
distributors. Pharmacogenomics, however, is specifically intended to uncover clinically important therapeutic differences within drug classes and
to identify new subcategories of disease based on genetic information. It is
conceivable that, over time, pharmacogenomics could overwhelm efforts to
contain the number of formulary disease categories and could create real
pressure to expand preferred drug listings for genetic subpopulations.
National Health Policy Forum | www.nhpf.org
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One frequently asked question is whether payers could limit coverage of
certain drugs to patients whose genetic profiles indicate that they are likely
to benefit from those drugs.59 Pharmacy coverage decisions generally follow any relevant FDA policies or label indications. Roughly ten percent of
currently marketed drugs have some pharmacogenomic information on
the label,60 but only a handful go so far as to require genetic testing prior
to prescribing the drug. Unless there is a very clear connection between
test findings and prescribing decisions, the FDA is less likely to require
the test on the label. Where the linkage appears clear, as in the case of Herceptin, the FDA has required labeling and testing, and coverage policies
have followed suit. Again, physicians can always opt to prescribe drugs
off label (in this case, in the absence of the genetic test), if in their professional judgment the patient would benefit from the drug. However, unless
a specific off-label use has become part of accepted medical practice or has
been shown effective in high-quality studies, there is a good chance that
a payer could deny reimbursement.
Reimbursement rates — Genetic tests generally are reimbursed under

the same pathology CPT (current procedural technology) coding system
and laboratory fee schedule as other laboratory tests. Payment amounts
for new tests are linked to payment levels for existing tests based on the
level of effort required to perform the test.61 (That is, whether a new test
diagnoses a common virus or a complex pattern of genetic variations does
not matter; if the two tests use the same laboratory technique, then they are
reimbursed roughly the same amount.) When a test uses a breakthrough
technology that has no precedent on the fee schedule, payers will conduct
technology assessments to set reimbursement rates as they do for any other
service. Currently, the Medicare laboratory fee schedule serves as the basis
for many private insurers’ laboratory reimbursement schedules. However,
the Medicare schedule was designed almost 20 years ago, and laboratory
testing technology has evolved so much since then that most experts agree
that the fee schedule amounts have little logical relationship to the services
they cover. In other words, labs are undercompensated for some tests and
may be overcompensated for others. The Medicare Modernization Act of
2003 froze the Medicare laboratory fee schedule until 2009; many hope it
will be comprehensively revised at that time.
Intellectual property — The pharmaceutical industry depends on intel-

lectual property law to protect its investment in innovation, but many are
concerned that current gene patenting and licensing practices could raise
the costs and slow the development of pharmacogenomic therapies.62 By
patenting genetic sequences63 or methods to detect them, patent holders
gain enormous control over all “downstream” commercial applications,
including the right to keep others from developing a drug to target or a
test to detect that gene.64 Multiple genes or regions of genes are usually
involved in regulating drug response; if competing entities hold patents
on any of those genes or regions, they could “block” each other from
developing a pharmacogenetic test unless they are willing to enter into
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a cross-licensing agreement. A report by the National Research Council
found evidence that licensing and royalty fees are already deterring laboratories from offering certain genetic tests.65 Laboratory directors have
testified that up-front flat fees and per-test royalties typically demanded
by licensing agreements add 15 percent or more to the cost of tests and
that such costs are not factored into existing laboratory fee schedules.66 As
pharmacogenomic tests become more complex and include more genes, the
need to negotiate multiple patents and cross-licensing agreements could
eventually make some tests too expensive or cumbersome for any but the
biggest laboratories to offer. It has been suggested that new intellectual
property concepts similar to patent pooling adopted in other industries
may be needed to keep tests affordable and accessible.67

As an incentive to drug companies
Novartis was able to secure orphan
Orphan Drugs
not to overlook small markets, the
status for Gleevec on the grounds
federal Orphan Drug Act provides
that the drug was indicated for
manufacturers who develop therapies for rare disa population of approximately 40,000 chronic
eases (those that affect fewer than 200,000 people)
myeloid leukemia patients with a particular chrosignificant financial and marketing subsidies,
mosomal abnormality. However, Gleevec has since
including grants for research and development,
been shown useful in treating a rare gastrointes“fast-track” approval, tax credits, non-negotiated
tinal tumor that has a mutation in a different but
pricing privileges, and a period of marketing
related gene, and in October 2006 it was approved
exclusivity against competing products. The Act
to treat yet another type of tumor as well as four
has been very successful, resulting in new drugs
rare blood diseases.§ Additional indications for the
for over 200 rare diseases, and the FDA is actively
drug likely will be found that are driven by a comencouraging drug companies to pursue pharmamon set of genes. Given the significant incentives
cogenomic approaches to more of the 6,000 remainconferred by the Act, drug developers may find it
ing orphan diseases identified by NIH.* However,
attractive to submit drugs whose initial application
from a regulatory standpoint, pharmacogenomics
would qualify for orphan drug status even before
could upend disease classification schemes and
formally testing the drug for different indications
basic assumptions about what constitutes a rare
that may share the same underlying mechanism.
†
disease. Many relatively common diseases, like
At some point, understanding these mechanisms
breast cancers, can now be subdivided on the bacould lead to a redefinition of rare disease; in the
sis of genomics into distinct and sometimes rare
meantime the FDA will need to strike a careful
subtypes that require different drug therapies. It
balance between encouraging orphan drug apis just as possible that diverse rare diseases may
plications to stimulate risky pharmacogenomics
turn out to share molecular genetic disease process
research and ensuring that those applications
that are amenable to the same drug.‡ For example,
remain consistent with the intent of the Act.
* The Office of Rare Diseases at the NIH maintains a list of rare diseases and conditions at http://rarediseases.info.nih.gov/asp/diseases/diseases.asp.
† Paul D. Maher and Marlene Haffner, “Orphan Drug Designation and Pharmacogenomics: Options and Opportunities,” BioDrugs, 20, no. 2
(2006): pp. 71–79.
‡ Jai Shah, “Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare,” Nature Biotechnology, 21, no. 7
(July 2003): pp. 747–753.
§ “Novartis Drug Wins Expanded FDA Approval,” Associated Press, October 19, 2006.
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Physician uptake — Despite its apparent advantages over trial-and-error

prescribing, pharmacogenomics will probably not be embraced by physicians in the absence of significant incentives to compensate for the extra
time and education that will be needed to integrate this technology into
their practices. Many physicians consider their diagnostic skills and prescribing decisions part of the “art” of medicine and will demand convincing
evidence that information from genetic test results adds clinical value and
leads to better outcomes for their patients. From a physicians’ perspective,
pharmacogenomics may only complicate prescribing and drug dispensing
by requiring an extra diagnostic step that includes additional paperwork,
delays in care while waiting for the laboratory report, and longer patient
visits to explain the complex results. Past experience in trying to change
physician practice patterns, for example, to improve rates of preventive
services and encourage adoption of electronic medical records, has demonstrated the need to provide strong incentives through reimbursement and
performance feedback. However, creating appropriate practice incentives
for pharmacogenomics could be very challenging given already daunting
budgetary issues in Medicare Part B and competing priorities in quality
and performance measurement systems.

Cost
It is often asserted that pharmacogenomics will produce cost savings to
the health care system through better patient care and reduced drug development costs. These claims are difficult to evaluate at this early stage of
the technology’s development. It is also possible that pharmacogenomics
could contribute to increasing health care costs.
Important sources of potential cost savings include a reduction in the number of adverse drug reactions that not only place patients in danger but
often result in emergency room visits and expensive rehabilitative care,68
as well as the development of more effective therapies that require fewer
return visits to physicians (and free up health care resources). For example,
a recent effort to model savings from integrating genetic testing into routine
warfarin therapy concluded that warfarin users in the United States would
avoid 85,000 serious bleeding events and 17,000 strokes annually and save
$1.1 billion each year.69 If pharmacogenomics enables doctors to prescribe
more accurately and results in faster, more effective therapy with fewer side
effects, it could indeed deliver savings throughout the health care system.
Supporters also anticipate cost savings from streamlining drug development. The Boston Consulting Group estimates that targeted drug development techniques could shave up to $335 million and two years off the
cost of bringing a new drug to market, mostly through shortening the time
needed for clinical trials.70
On the other hand, there are reasons to be skeptical that pharmacogenomics will be able to reduce health care costs overall. First, in order
to significantly reduce the number of ineffective therapies and adverse
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drug reactions, genetic testing and targeted prescribing would have to
be widely deployed, and as noted earlier, there is little incentive for drug
manufacturers to undertake the expense of developing or promoting
pharmacogenomic tests for drugs that are already on the market. Public
sector efforts, such as the PGRN and EGAPP have stepped in to develop
and synthesize the scientific and clinical research base for some of the most
often implicated drugs, but these efforts will take time. Getting specific
findings, including pharmacogenomic testing and prescribing guidance,
into the hands of receptive physicians and other health care professionals
remains a challenge.
Second, most experts anticipate that companies will
demand higher prices per unit of pharmacogenomi- Whether pharmacogenomics will
cally tailored drugs to make up for the smaller potential reduce the cost of clinical trials is
market. Indeed, companies already have demonstrated
still an open question.
that they are willing to set and hold premium prices for
pharmacogenomic tests and targeted therapeutics, even under intense
public criticism.71 Moreover, new pharmacogenomic drugs will be patentprotected from generic competition for many years. Some suggest that the
very biological precision that enables the new targeted drugs to command
high prices will enable would-be competitors to “invent around” patented
products by targeting different molecules in the same disease pathway,
or by targeting the same molecule using a different mode of action.72 So
far, however, there is little evidence from today’s drug marketplace that
inventing around will put any significant downward pressure on price.
Third, whether pharmacogenomics will reduce the cost of clinical trials is
still an open question. Currently, clinical trials in which subjects’ genetic
variations are taken into consideration may be more expensive to operate
than those trials where no genetic data are used.73 According to a trade
publication, “There is no question that applying pharmacogenomics to
clinical trials increases the cost. There is added cost in the preclinical stages,
where biomarkers must be identified and validated. Then there is extra
cost in the clinic, where study design needs to take genetics into consideration….Using a pharmacogenomic approach could even slow down clinical
trials if you must seek out a patient population that is enriched for your
trial.”74 Over the longer term, as technologies for identifying biomarkers
and managing patient information evolve, it is possible that some of these
costs may come down,75 and it is possible that such trials will indeed be
shorter, enabling the hoped-for savings in comparison to traditional trials.
Whether overall savings are achieved will likely depend on the relative
proportion of targeted (versus blockbuster) drug candidates for whom
streamlined trials are appropriate.
Fourth, although pharmacogenomics may create opportunities to “rescue”
failed drugs, it remains to be seen whether and under what circumstances
pharmaceutical companies will find that option economically viable. Because
intellectual property claims are filed long before regulatory approval, there
will likely be limited life remaining on the original drug, compounded by
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the additional time involved for further testing that the FDA likely would
require.76 One possible scenario is illustrated by the multiple sclerosis drug
Tysabri, which was pulled from the market in 2004 after concerns about a
potentially dangerous side effect. The drug was reintroduced a year later
with a label for a smaller population, a controlled distribution system to
ensure that it is only given to patients for whom the risk is justified, and a
price increase of 21 percent (to $28,400 per year).77
Fifth, it is possible that this technology can be used to exploit incentives
in the current drug approval and reimbursement systems in ways that
raise costs for consumers and the health care system overall. For example,
as noted previously, health plans pay for drugs according to formularies
that attempt to control costs by including a limited number of therapeutically equivalent drugs and negotiating pricing on the basis of formulary
placement and tiering. However, if a drug maker can show, using pharmacogenomics techniques, that a particular drug produces a statistically
better result (even if only marginally so) for a genetically defined group of
patients, it may be able to differentiate a “me too” product into a “me only”
drug, creating pressure to include it on the formulary at least for that group
of patients.78 As one pharmaceutical company executive has noted, “Even
average drugs can become ‘superdrugs’ in the right population.”79
Finally, some worry that pharmacogenomics will add costs without adding
value. For example, very expensive drugs could be used in populations or for
indications beyond those for whom they are designed, as has happened with
Herceptin. Test-drug combinations may not produce clinically meaningful
improvements in patient outcomes over current therapies. Or genetic testing
could turn up lots of potentially “abnormal” results that are not clinically
relevant but that would require massive additional resources to rule out. In
the absence of comparative effectiveness and cost-benefit data that can assess
the value of this technology as it evolves, such developments could be very
challenging for policymakers and health care institutions to manage.
In addition, pharmacogenomics will certainly add direct service costs for
genetic testing, data collection and analysis, and counseling. One expert
summarized the issue this way: “It will be more cost effective, but it will
not be cost saving. So you’ll pay more and you’ll get more, but you will
not save money.”80

Ethical Considerations
The ethical, legal, and social implications of pharmacogenomics have been
widely acknowledged. In particular, issues associated with personal genetic data collection, use, and interpretation will require careful handling
by policymakers.
Patient privacy — Many believe that statutory protection against dis-

crimination on the basis of genetic information is an essential condition
for pharmacogenomics to succeed. It is well documented that people will
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hesitate or even refuse to participate in genetics research, take advantage
of potentially helpful genetic tests, or disclose medical history information if they fear their data could be misused or their privacy violated. In a
2003 study on hereditary colon cancer, 39 percent of patients identified the
potential effect on their health insurance as the most important reason not
to undergo genetic testing to find out if they carried one of several known
predisposing genes for the disease.81 Other observers have argued that it is
unreasonable to single out genetic information for special protection given
all the other biological sources of potential stigma, such as HIV status.
Guidelines for sample collection and storage — To be ethically valid, re-

It is well documented
that people will hesitate or even refuse to
participate in genetics
research…if they fear
their data could be
misused or their privacy violated.

quests for patient consent to use identifiable biological samples in research
must be clear about the purpose of the research, how the samples will
be used, and who will have access to them. If these parameters change,
patient consent must often be obtained again. What are the appropriate
standards for security, access, and informed consent when patient DNA
samples are being gathered as a routine part of clinical trials and stored
for future exploratory analysis?
Collateral information — While pharmacogenomic tests to inform prescrib-

ing decisions may not be as sensitive per se as other types of genetic tests,
it is possible that testing will turn up additional information about disease
predisposition or progression that may be more information than people
want. For example, the known association of the gene ApoE with Alzheimer’s
disease was identified during research on the polymorphisms of familial
hyperlipoproteinemia (a form of cardiovascular disease).82 Procedures to
gather the patient’s preferences for handling such collateral information—to
tell or not to tell—will need to be developed and implemented.83
Race and pharmacogenomics — Many gene variants vary with geographic
ancestry, including variants that are associated with drug response,84 and indeed physicians have long recognized that race can be an important variable
in predicting how individuals will respond to certain medications. Researchers
are now exploring the contribution of racial genetics to drug safety and efficacy.
For example, researchers at the University of California at Los Angeles are
looking for genetic factors that specifically influence how Mexican Americans,
African Americans, and whites respond to several different antidepressants.
FDA recently has required manufacturers of carbamazepine (used to treat
epilepsy, bipolar disorder, and neuropathic pain) to warn on the label that
patients of Asian ancestry are at risk for a rare but severe skin reaction from
the drug and should have a genetic test before starting treatment. However,
there are many social and scientific arguments both for and against the use
of race and ethnicity to categorize subjects in pharmacogenomic research and
practice. The FDA’s decision to approve the drug Bi-Dil for treatment of heart
failure only in self-identified African Americans—the only subpopulation
in which the clinical trial showed benefit—helped to crystallize the debate.
Critics warned that drug research, development and approval based on the
genetics of particular population groups could lead to new forms of social or
medical stigmatization.85 They also pointed out that the correlation between
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self-identified race and genetic ancestry is highly imperfect, particularly as
multi-racial backgrounds become more common, and that a higher prevalence
of a genetic variant in a racial or ethnic population does not predict whether
any given individual member of that racial or ethnic group will have the
variant. In addition, critics worry that distinctions based on race, rather than
pathophysiology, might be trumped up for commercial advantage.86 Supporters of FDA’s decision argued that in the absence of more precise categories to
identify responders versus non responders to the drug, self-identified race was
the best available proxy to determine who will benefit (and who not) from a
medication shown to be effective against a disease with high morbidity and
mortality. Choosing to ignore the distinctions or waiting for different criteria
to be developed would deny access to this useful drug to those who could
benefit from it.87 Ultimately, pharmacogenomic research may provide its own
key to this dilemma, by developing more accurate and specific descriptions
of relevant genetic variations that could replace imprecise racial and/or ethnic
categories in predicting drug response.

CONCLUSION
Many believe that pharmacogenomics offers enormous potential for improving drug safety and effectiveness as well as the productivity of the drug
development pipeline. Indeed it is possible that some day each individual
will carry his or her unique genetic profile on a chip that physicians will
consult before prescribing. Today, however, only a small number of drugs
are associated with a genetic test to determine whether that drug is appropriate for a given patient.
Bringing pharmacogenomics from the realm of basic exploratory genetics research to safe, effective applications in the doctor’s office will not
be easy or inexpensive. It will require enormous investment and collaboration among a multitude of players, including the pharmaceutical,
biotechnology, and diagnostics industries; their federal regulators; thirdparty payers; health professionals and the institutions that train them;
health information technology planners; and many others. The science
is immensely challenging, and the cost of research needed to translate
scientific findings into clinically useful tools is high. Significant issues
arise from the current business models of the pharmaceutical, biotechnology, and diagnostics industries, overlaid with the need to update the
regulatory framework to address potential safety issues while supporting
the development of pharmacogenomic products. There are additional
challenges that accompany the integration of any new technology into
modern health care, including the need to prove value to the health care
system, to manage uptake through appropriate coverage and reimbursement policies and provider education, and to anticipate potentially significant ethical and social implications. Few of these issues are unique to
pharmacogenomics, but all will need to be explicitly considered in the
context of this technology.
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